GLP-1 vs Adiponectin
Head-to-head comparison of GLP-1 (Glucagon-like peptide-1 (7-36 amide)) and Adiponectin (Adiponectin (Acrp30, AdipoQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | GLP-1 | Adiponectin |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Glucagon-like peptide-1 (7-36 amide) | Adiponectin (Acrp30, AdipoQ) |
| Molecular Weight | 3297 Da | ~26.4 kDa (monomer) |
| Half-Life | 1-2 minutes | ~2-4 h |
| Amino Acids | 30 | 244 |
| Typical Dose | Research-only: 0.1-1.0 pmol/kg/min | No approved human dose; research use only |
| Route | Intravenous/Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 86 |
| Research Status | Pre-clinical | Pre-clinical |
GLP-1 Benefits
- ✓beta-cell protection
- ✓improved insulin secretion
- ✓slower gastric emptying
- ✓lower postprandial glucose
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
GLP-1 Dosing
0.1-1.0 pmol/kg/min IV infusion in research|0.5-10 nM in vitro|continuous delivery in animal studies
Adiponectin Dosing
not established|not established
GLP-1 Side Effects
- ⚠nausea at pharmacologic exposure
- ⚠tachyphylaxis with continuous exposure
- ⚠headache
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
GLP-1
Native GLP-1 has a very short half-life because of rapid DPP-4 cleavage, so it is mainly used as a mechanistic research peptide. Across animal and cellular studies it reduces beta-cell apoptosis, improves insulin gene expression, and enhances islet resilience.
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.